Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKesson
Baxter
Express Scripts
Dow

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Emricasan


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Emricasan?

Emricasan is an investigational drug.

There have been 15 clinical trials for Emricasan. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, and Fatty Liver. The leading clinical trial sponsors are Conatus Pharmaceuticals Inc., Histogen, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).

There are one hundred and ninety-one US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Emricasan
TitleSponsorPhase
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19HistogenPhase 1
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisConatus Pharmaceuticals Inc.Phase 2
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal HypertensionConatus Pharmaceuticals Inc.Phase 2

See all Emricasan clinical trials

Clinical Trial Summary for Emricasan

Top disease conditions for Emricasan
Top clinical trial sponsors for Emricasan

See all Emricasan clinical trials

US Patents for Emricasan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Emricasan ⤷  Try it Free Methods of treating, inhibiting and/or preventing an auditory impairment The United States of America as represented by the Department of Veterans Affairs (Washington, DC) ⤷  Try it Free
Emricasan ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Emricasan ⤷  Try it Free Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells Massachusetts Eye and Ear Infirmary (Boston, MA) ⤷  Try it Free
Emricasan ⤷  Try it Free Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors Pfizer Inc. (New York, NY) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Emricasan

Drugname Country Document Number Estimated Expiration Related US Patent
Emricasan Australia AU2017261372 2036-05-05 ⤷  Try it Free
Emricasan Canada CA3023278 2036-05-05 ⤷  Try it Free
Emricasan China CN107847398 2036-05-05 ⤷  Try it Free
Emricasan European Patent Office EP3452003 2036-05-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKesson
Baxter
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.